Maimonides Medical Center
Trial Pipeline
Intracervical Balloon Placement With Nitrous Oxide Administration
NCT06498908
Impact of Bright Light Therapy on Prader-Willi Syndrome
NCT05939453
Fibulink Syndesmosis Repair System With Early Full-Weight Bearing
NCT06085586
Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo
NCT04807894
Reduction of Prostate Biopsy Morbidity
NCT03913039
Hip Fracture Exparel Administration Trial Capsule During Hemiarthroplasty
NCT03502018
Comparative Study of Two Different Techniques to Perform TAP-blocks
NCT02571439
Vitamin D Increases Serum Levels of the Soluble Receptor for Advanced Glycation End Products in Women With PCOS
NCT03644212
Clinical and Microbiological Outcomes of Infections Due to Carbapenem-Resistant Gram-Negative Bacteria
NCT01041716
Frequency of Formula Change Prior to the Accurate Diagnosis of Pyloric Stenosis
NCT00409734
Study of the Need for Temperature Probe Covers for Newborn Babies on Radiant Warmers
NCT00312065
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 1 |
| Phase 4 | 4 |
What the Pipeline for Maimonides Medical Center Shows
According to the ClinicalTrials.gov registry, Maimonides Medical Center is linked to 11 US clinical trials across every stage of research activity. Of those, 4 studies are currently recruiting — about 36% of the sponsor's indexed portfolio — and 7 are already marked complete, representing roughly 64% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Maimonides Medical Center reports 5 late-stage studies (Phase 3 and Phase 4 combined) and 1 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Maimonides Medical Center is Hip Hemiarthroplasty with 1 linked trial, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.